Association of cognitive dysfunction with cardiovascular disease events in elderly hypertensive patients.

Objectives: This study assesses whether presence of cognitive dysfunction can be a marker associated with the development of cardiovascular disease (CVD) events independent of ambulatory blood pressure (BP) or other indices of target organ damage (TOD) in elderly hypertensive patients.

Methods: We recruited 585 hypertensive patients (mean age, 73 years; 41% men) who were ambulatory, lived independently, and were without clinically overt dementia. Cognitive function was assessed by Mini-Mental State Examination (MMSE) at baseline, and CVD events (coronary artery disease, stroke, congestive heart failure, and sudden death) were prospectively ascertained.

Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes.

Background: To examine the effects of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the advanced glycation end product (AGE)-receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes patients.

Methods: Sixty-one patients whose HbAlc  ≥ 6.1% (mean age 64.

Nighttime blood pressure, nighttime glucose values, and target-organ damages in treated type 2 diabetes patients.

Objective: The associations between nighttime blood pressure (BP) and cardiovascular risk are well established. However, the associations between nighttime glucose values, including nocturnal hypoglycemia, and cardiovascular risk in diabetes remain unclear.

Methods: In this cross-sectional study of 49 treated type 2 diabetes patients (mean, 67.